BRPI0514386A - sal do ácido n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fe nóxi]pentóxi}benzamidina-2-metanossulfÈnico - Google Patents

sal do ácido n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fe nóxi]pentóxi}benzamidina-2-metanossulfÈnico

Info

Publication number
BRPI0514386A
BRPI0514386A BRPI0514386-1A BRPI0514386A BRPI0514386A BR PI0514386 A BRPI0514386 A BR PI0514386A BR PI0514386 A BRPI0514386 A BR PI0514386A BR PI0514386 A BRPI0514386 A BR PI0514386A
Authority
BR
Brazil
Prior art keywords
benzamidine
pentoxy
phenoxy
isopropyl
hydroxy
Prior art date
Application number
BRPI0514386-1A
Other languages
English (en)
Inventor
Jei Wan Ryu
Jin Soo Lee
Dong Hyuk Shin
Seung Kyoo Seong
Soon Ki Cho
Chan Seok Jeon
Young Goo Jin
Ki Young Lee
Se Hyun Jung
Eun Hee Cho
Seok Hoon Ahn
Original Assignee
Dong Wha Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong Wha Pharm Ind Co Ltd filed Critical Dong Wha Pharm Ind Co Ltd
Publication of BRPI0514386A publication Critical patent/BRPI0514386A/pt
Publication of BRPI0514386B1 publication Critical patent/BRPI0514386B1/pt
Publication of BRPI0514386B8 publication Critical patent/BRPI0514386B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SAL DO áCIDO N-HIDRóXI-4-{5-¢4-(5-ISOPROPIL-2-METIL-1,3-TRIAZOL-4-IL)FE NóXI!PENTóXI}BENZAMIDINA-2-META-NOSSULFÈNICO. A presente invenção refere-se a um sal do ácido de N-hidróxi-4-{5-¢4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi!pentóxi}ben zamidina-2-meta-nossulfónico, que apresenta excelente biodisponibilidade. São também descritas um método de preparação do composto e uma composição farmacêutica contendo o composto.
BRPI0514386A 2004-11-23 2005-11-22 bis (metanossulfonato) de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina, método para preparar os mesmos, suas composições farmacêuticas e formulações orais BRPI0514386B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20040096390 2004-11-23
KR10-2004-0096390 2004-11-23
PCT/KR2005/003934 WO2006057501A1 (en) 2004-11-23 2005-11-22 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Publications (3)

Publication Number Publication Date
BRPI0514386A true BRPI0514386A (pt) 2008-06-10
BRPI0514386B1 BRPI0514386B1 (pt) 2021-02-09
BRPI0514386B8 BRPI0514386B8 (pt) 2021-05-25

Family

ID=36498212

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0517396-5A BRPI0517396A (pt) 2004-11-23 2005-11-22 preparação oral com melhor biodisponibilidade
BRPI0514386A BRPI0514386B8 (pt) 2004-11-23 2005-11-22 bis (metanossulfonato) de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina, método para preparar os mesmos, suas composições farmacêuticas e formulações orais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0517396-5A BRPI0517396A (pt) 2004-11-23 2005-11-22 preparação oral com melhor biodisponibilidade

Country Status (19)

Country Link
US (2) US20070254930A1 (pt)
EP (2) EP1701722B1 (pt)
JP (2) JP4774053B2 (pt)
KR (2) KR100716389B1 (pt)
CN (3) CN101693029B (pt)
AT (1) ATE445397T1 (pt)
AU (2) AU2005300239B2 (pt)
BR (2) BRPI0517396A (pt)
CA (2) CA2552766C (pt)
DE (1) DE602005017118D1 (pt)
DK (1) DK1701722T3 (pt)
ES (1) ES2333739T3 (pt)
HK (1) HK1094530A1 (pt)
IL (2) IL180985A (pt)
NZ (1) NZ555725A (pt)
PT (1) PT1701722E (pt)
RU (1) RU2361867C2 (pt)
WO (2) WO2006057507A1 (pt)
ZA (2) ZA200700485B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773333A4 (en) * 2004-07-05 2010-04-21 Dong Wha Pharm Co Ltd COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALLERGIC INFLAMMATORY DISEASES
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
WO2006057507A1 (en) * 2004-11-23 2006-06-01 Dong Wha Pharm.Ind.Co., Ltd An oral preparation having improved bioavailability
ATE494282T1 (de) * 2007-04-19 2011-01-15 Dong Wha Pharm Co Ltd 2-ethansulfonsäuresalz aus n- hydroxy-4-ä5-ä4-(5- isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxyüpentoxyü benzamidin, verfahren zu seiner herstellung und pharmazeutische zusammensetzung damit
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
JP6379044B2 (ja) * 2013-01-31 2018-08-22 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016175230A1 (ja) 2015-04-28 2016-11-03 アステラス製薬株式会社 経口投与用医薬組成物
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
SG11202001436YA (en) * 2017-08-18 2020-03-30 Abbvie Inc Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
EP0379579A4 (en) * 1988-02-03 1991-01-02 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
PA8441701A1 (es) * 1996-11-26 2000-05-24 Pfizer Sales dimesilato de los ligandos del neuropeptido y
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
AU776193B2 (en) * 1999-10-28 2004-09-02 Sankyo Company Limited Benzamidine derivatives
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
DK1490024T3 (da) * 2002-03-06 2012-04-10 Effrx Pharmaceuticals Sa Alendronatholdige brusesammensætninger
MXPA04009960A (es) * 2002-04-12 2004-12-13 Pfizer Compuestos de pirazol como agentes anti-inflamatorios y analgesicos.
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
KR101173580B1 (ko) * 2003-03-18 2012-08-13 코와 가부시키가이샤 제산제 조성물
WO2006057507A1 (en) * 2004-11-23 2006-06-01 Dong Wha Pharm.Ind.Co., Ltd An oral preparation having improved bioavailability

Also Published As

Publication number Publication date
CN101693029A (zh) 2010-04-14
AU2005300239B2 (en) 2009-08-06
CA2552766C (en) 2010-08-17
ATE445397T1 (de) 2009-10-15
KR20060057511A (ko) 2006-05-26
AU2005307994A1 (en) 2006-06-01
EP1701722A4 (en) 2007-05-16
ZA200704236B (en) 2008-11-26
DE602005017118D1 (de) 2009-11-26
IL182647A0 (en) 2007-07-24
ES2333739T3 (es) 2010-02-26
WO2006057507A1 (en) 2006-06-01
US20090176846A1 (en) 2009-07-09
EP1701722B1 (en) 2009-10-14
CN101056658A (zh) 2007-10-17
WO2006057501A1 (en) 2006-06-01
RU2007123614A (ru) 2008-12-27
KR20060057514A (ko) 2006-05-26
CA2585003C (en) 2010-08-17
JP2008508264A (ja) 2008-03-21
BRPI0514386B1 (pt) 2021-02-09
CN1905871A (zh) 2007-01-31
CN101693029B (zh) 2011-11-02
BRPI0514386B8 (pt) 2021-05-25
KR101047042B1 (ko) 2011-07-06
BRPI0517396A (pt) 2008-10-14
PT1701722E (pt) 2009-12-10
CN100574756C (zh) 2009-12-30
AU2005307994B2 (en) 2009-07-23
CN1905871B (zh) 2010-07-07
US20070254930A1 (en) 2007-11-01
CA2585003A1 (en) 2006-06-01
ZA200700485B (en) 2007-11-28
EP1701722A1 (en) 2006-09-20
IL180985A (en) 2012-02-29
JP4773456B2 (ja) 2011-09-14
HK1094530A1 (en) 2007-04-04
JP2008520655A (ja) 2008-06-19
EP1814593A4 (en) 2012-09-05
KR100716389B1 (ko) 2007-05-11
DK1701722T3 (da) 2010-01-11
CA2552766A1 (en) 2006-06-01
RU2361867C2 (ru) 2009-07-20
JP4774053B2 (ja) 2011-09-14
IL182647A (en) 2011-04-28
AU2005300239A1 (en) 2006-07-06
NZ555725A (en) 2008-07-31
IL180985A0 (en) 2007-07-04
EP1814593A1 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
BRPI0514386A (pt) sal do ácido n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fe nóxi]pentóxi}benzamidina-2-metanossulfÈnico
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
NZ594537A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2003097622A3 (en) Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof
BRPI0516904A (pt) processo para a preparação de um derivado de 2-etilaminopiridina e composto
AR047541A1 (es) Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
MX2010001773A (es) Metodo para preparar derivados de 5-haloalquil-4,5-dihidroisoxasol .
WO2007033780A3 (de) Thiazole als fungizide
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
UA92354C2 (en) Amino acid salts of rosiglitazone
WO2011021214A3 (en) Improved process for preparing (s)-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)benzothiazole and its dhtydrochloride monohydrate
MX2008001612A (es) Metodos para preparar acidos boronicos heterociclicos y derivados de los mismos.
BRPI0607085A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes
ATE469156T1 (de) 3,4 diaminopyridin-derivate
WO2005012273A3 (en) Process for the preparation of substituted thiazoles
WO2006030197A3 (en) Radiolabelled insulin
DE60115062D1 (de) Ein thiazolidindionderivat und seine verwendung als antidiabetikum
WO2006021654A8 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
EA200300230A1 (ru) Тартратная соль производного тиазолидиндиона
DE60124119D1 (de) Ein thiazolidindionderivat und seine verwendung als antidiabetikum
AU2003269483A1 (en) Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
CA2257322A1 (en) Thiazole derivatives
EA200300231A1 (ru) Тартратные соли производного тиазолидиндиона
BRPI0513034A (pt) processo aperfeiçoado para preparação de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1, 3-tiazol-4-il)-fenóxi]-pentóxi}-benzamidina
EA200700003A1 (ru) Соль фосфорной кислоты и 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона и способ её получения

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF